The promise of transformative cures for rare and serious diseases is at the forefront of medical innovation with gene therapies. Yet despite impressive scientific advances and regulatory approvals, the broader adoption of these treatments remains puzzlingly slow. There are multiple contributing factors, from infrastructure and logistics complexities to awareness and reimbursement challenges, that may explain why uptake is not keeping up with the expectations.
Gaps in awareness and education
One of the biggest barriers to gene therapy adoption is awareness. Several patients, caregivers and even healthcare professionals (HCPs) might not know about the potential and workings of these treatments. Several providers also seem to be hesitant, in part because of safety concerns that are based on past knowledge of earlier gene therapy services. To address this challenge, pharmaceutical companies must engage in actively educating institutions, support patient and caregiver education and set up structured follow-ups post-treatment.
Operational and infrastructure challenges
The delivery ecosystem is another significant obstacle. The costs and complexities of setting up and operating gene therapies are high because numerous centers of excellence (COEs) are needed to provide specialized storage, freezing, decontamination and highly skilled staff. The business case for setting up and running a treatment facility becomes risky since patient volumes per center are often unpredictable.
Logistical and administrative burden
Another challenge to the widespread adoption of gene therapy is the logistics involved, which can create a significant administrative burden for institutions that plan to take on gene therapies. Many centers deal with the challenges of onboarding, placing orders and certification processes for each therapy. There are also various logistics protocols in place for various products, which further complicates adoption for a majority of healthcare providers. These challenges also discourage many potential sites from participating in gene therapy adoption, which further reduces access and slows down adoption.
Commercial and reimbursement hurdles
From a business standpoint, expanding these treatments beyond rare diseases is still challenging. The small number of eligible patients in many cases, along with the high cost of therapy and the uncertain long-term effectiveness, causes payers and manufacturers to be careful. Therefore, even as more gene therapies get approval, the system still does not have consistent ways for broad implementation.
The role of advanced technologies
Advanced technologies like artificial intelligence (AI) may be able to help healthcare providers. Broader technologies, like generative AI technology, hold the potential to support patient-identification, treatment logistics and monitoring. When applied thoughtfully, advanced analytics and AI-driven patient segmentation could help identify eligible patients earlier, optimize treatment centers, streamline supply chains and ultimately lower cost of access. In this context, leveraging gene therapy alongside data-enabled insights becomes increasingly important to overcome systemic barriers.
Ecosystem and market readiness
To reach full potential of gene therapy solutions, the current ecosystem must evolve alongside science. Manufacturers need to work together with providers, advocacy groups and registries to support long-term follow-up studies, capture real-world outcomes and create patient-outcome databases. Without this basic infrastructure, groundbreaking treatments will have a hard time reaching everyone who needs them.
Though adoption of gene therapy may be low currently, there is clear hope for the future. If industry players can tackle the challenges related to education, infrastructure and logistics, gene therapy adoption can speed up.
